U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552376) titled 'This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.' on April 20.

Brief Summary: The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: MSI-H or dMMR Advanced Solid Tumors

Intervention: DRUG: QLS1317

Varying doses of QLS1317

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD

Disclaimer: Curated by HT Syndication....